Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Returns
Return on equity-31.1%-25.2%-38.1%
Return on assets-26.9%+12.6pp-22.4%+21.4pp-32.2%+36.2pp-42.4%+12.3pp-39.5%+95.4pp
Liquidity
Current ratio+0.9×13.3×+2.0×10.9×+3.6×6.5×-13.2×8.1×-3.3×
Quick ratio+0.9×13.3×+2.0×10.9×+3.6×6.5×-13.2×8.1×-3.3×
Cash ratio1.1×+0.5×1.5×-0.2×1.4×+0.2×-1.1×0.7×-4.6×
Per Share
Book value per share$8.54+6.6%$11.17+1.4%$7.53+17.1%$7.55-8.6%$8.01+92.0%
Valuation
Market capitalization$3.96B+307%$2.54B+82.6%$1.01B-32.4%$930.05M-22.1%$972.25M-29.1%
Price / book5.9×+3.9×3.6×+0.9×2.2×-2.3×
Earnings yield-4.5%+17.0pp-6.1%+8.8pp-14.7%-0.4pp-22.2%-6.7pp-21.5%+5.1pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Spyre Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Spyre Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.